Steeg PS, Camphausen KA, Smith QR. Brain Metastases as Preventive and Therapeutic Targets. Nat Rev Cancer 2011;11:352-63.
Khanfir A, Lahiani F, Bouzguenda R, et al. Prognostic Factors and Survival in Metastatic Breast Cancer: A Single Institution Experience. Rep Pract Oncol Radiother 2013;18:127-32.
Ranjan T, Abrey LE. Current Management of Metastatic Brain Disease. Neurotherapeutics 2009;6: 598-603.
Lu J, Steeg PS, Price JE, et al. Breast Cancer Metastasis: Challenges and Opportunities. Cancer Res 2009;69:4951-3.
Vona-Davis L, Rose DP, Gadiyaram V, et al. Breast Cancer Pathology, Receptor Status, and Patterns of Metastasis in a Rural Appalachian Population. J Cancer Epidemiol 2014;2014:170634.
Lin NU, Amiri-Kordestani L, Palmieri D, et al. CNS Metastases in Breast Cancer: Old Challenge, New Frontiers. Clin Cancer Res 2013;19:6404-18.
Eldredge HB, Denittis A, Duhadaway JB, et al. Concurrent Whole Brain Radiotherapy and Short-Course Chloroquine in Patients with Brain Metastases: a Pilot Trial. J Radiat Oncol 2013;2:315-21.
Nayak L, Lee EQ, Wen PY. Epidemiology of Brain Metastases. Curr Oncol Rep 2012;14:48-54.
Baselga J. Targeting Tyrosine Kinases in Cancer: the Second Wave. Science 2006;312:1175-8.
Renfrow JJ, Lesser GJ. Molecular Subtyping of Brain Metastases and Implications for Therapy. Curr Treat Options Oncol 2013;14:514-27.
Lin NU, Claus E, Sohl J, et al. Sites of Distant Recurrence and Clinical Outcomes in Patients with Metastatic Triple-Negative Breast Cancer: High Incidence of Central Nervous System Metastases. Cancer 2008; 113:2638-45.
Schouten LJ, Rutten J, Huveneers HA, et al. Incidence of Brain Metastases in a Cohort of Patients with Carcinoma of the Breast, Colon, Kidney, and Lung and Melanoma. Cancer 2002;94:2698-705.
Brabletz T, Lyden D, Steeg PS, et al. Roadblocks to Translational Advances on Metastasis Research. Nat Med 2013;19:1104-9.
Jia W, Lu R, Martin TA, et al. The Role of Claudin-5 in Blood-Brain Barrier (BBB) and Brain Metastases (Review). Mol Med Repts 2014;9:779-85.
Lin NU. Targeted Therapies in Brain Metastases. Curr Treat Options Neurol 2014;16:276.
Inoue S, Patil R, Portilla-Arias J, et al. Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer. PLoS One 2012; 7:e31070.
Markman JL, Rekechenetskiy A, Holler E, et al. Nanomedicine Therapeutic Approaches to Overcome Cancer Drug Resistance. Adv Drug Deliv Rev 2013;65:1866-79.
Pardridge WM. Blood-Brain Barrier Drug Delivery of IgG Fusion Proteins with a Transferrin Receptor Monoclonal Antibody. Expert Opin Drug Deliv 2015;12:207-22.
Bickel U, Yoshikawa T, Pardridge WM. Delivery of Peptides and Proteins Through the Blood-Brain Barrier. Adv Drug Deliv Rev 2001;46:247-79.
Daniels TR, Bernabeu E, Rodriguez JA, et al. The Transferrin Receptor and the Targeted Delivery of Therapeutic Agents Against Cancer. Biochim Biophys Acta 2012; 1820:291-317.
Ljubimova JY, Portilla-Arias J, Patil R, et al. Toxicity and Efficacy Evaluation of Multiple Targeted Polymalic Acid Conjugates for Triple-Negative Breast Cancer Treatment. J Drug Target 2013;21:956-67.
Lee BS, Fujita M, Khazenzon NM, et al. Polycefin, a New Prototype of a Multifunctional Nanoconjugate Based on Poly (↕-L-Malic Acid) for Drug Delivery. Bioconjug Chem 2006;17:317-26.
Inoue S, Ding H, Portilla-Arias J, et al. Polymalic Acid- Based Nanobiopolymer Provides Efficient Systemic Breast Cancer Treatment by Inhibiting Both HER2/Neu Receptor Synthesis and Activity. Cancer Res 2011; 71:1454-64.
Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18:2349-51.
Sun M, Behrens C, Feng L, et al. HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors. Clin Cancer Res 2009; 15:4829-37.
Hu J, Ljubimova JY, Inoue S, et al. Phosphodiesterase Type 5 Inhibitors Increase Herceptin Transport and Treatment Efficacy in Mouse Metastatic Brain Tumor Models. PLoS One 2010;5:e10108.
Emlet DR, Gupta P, Holgado-Madruga M, et al. Targeting a Glioblastoma Cancer Stem-Cell Population Defined by EGF Receptor Variant III. Cancer Res 2014;74:1238-49.
Moelling K, Schad K, Bosse M, et al. Regulation of Raf-Akt Cross-Talk. J Biol Chem 2002;277:31099-106.
Chautard E, Ouedraogo ZG, Biau J, et al. Role of Akt in Human Malignant Glioma: from Oncogenesis to Tumor Aggressiveness. J Neurooncol 2014;117:205-15.
Ding H, Inoue S, Ljubimov AV, et al. Inhibition of Brain Tumor Growth by Intravenous Poly (↕-L-Malic Acid) Nanobioconjugate with Ph-Dependent Drug Release. Proc Natl Acad Sci USA 2010;107:18143-8.
Langer R, Weissleder, R. Nanotechnology. JAMA 2015; 313:135-6.
Hatake K, Tokudome N, Ito Y. Next Generation Molecular Targeted Agents for Breast Cancer: Focus on EGFR and VEGFR Pathways. Breast Cancer 2007;14:132-49.
Peddi PF, Hurvitz SA. PI3K Pathway Inhibitors for the Treatment of Brain Metastases with a Focus on HER2+ Breast Cancer. J Neurooncol 2014;117:7-13.
Butte PV, Fang Q, Jo JA, et al. Intra-operative delineation of primary brain tumors using time-resolved fluorescence spectroscopy. μJ Biomed Opt§ 2010;15:027008.
Butte PV, Pikul BK, Hever A, et al. Diagnosis of meningioma by time-resolved fluorescence spectroscopy. J Biomed Opt 2005;10:064026.
Butte PV, Mamelak AN, Nuno M, et al. Fluorescence lifetime spectroscopy for guided therapy of brain tumors. Neuroimage 2011;54 Suppl 1:S125-35.
Lin WC, Toms SA, Johnson M, et al. In Vivo Brain Tumor Demarcation Using Optical Spectroscopy. μPhotochem Photobiol§ 2001;73:396-402.
Lin WC, Sandberg DI, Bhatia S, et al. Optical spectroscopy for in-vitro differentiation of pediatric neoplastic and epileptogenic brain lesions. μJ Biomed Opt§ 2009; 14:014028.
Liu Q, Grant G, Li J, et al. Compact point-detection fluorescence spectroscopy system for quantifying intrinsic fluorescence redox ratio in brain cancer diagnostics. J Biomed Opt 2011;16:037004.
Alzheimer’s Disease International (ADI). Policy Brief for Heads of Government The Global Impact of Dementia 2013-2050:3.(Accessed July 20, 2015 at http://www.alz.co.uk/research/GlobalImpactDementia2013.pdf).
Alzheimer’s Disease International (ADI). World Alzheimer Report 2010: The Global Economic Impact of Dementia. (Accessed July 20, 2015 at http://www.alz.co.uk/research/world-report-2010).
World Health Organization. Dementia: A Public Health Priority. (Accessed July 20, 2015 at http://www.who.int/ mental_health/publications/dementia_report_2012).
Hardy J, Selkoe DJ. The amyloid hypothesis of alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002;297:353-6.
Trojanowski JQ, Schmidt ML, Shin RW, et al. Altered tau and neurofilament proteins in neuro-degenerative diseases: Diagnostic implications for alzheimer’s disease and lewy body dementias. Brain Pathol 1993;3:45-5.
Lee VM.Regulation of tau phosphorylation in alzheimer’s disease. Ann N Y Acad Sci 1996;777:107-13.
Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the national institute on aging-alzheimer’s association workgroups on diagnostic guidelines for alzheimer’s disease. Alzheimers Dement 2011;7:257-62.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of alzheimer’s disease: Recommendations from the national institute on aging-alzheimer’s association workgroups on diagnostic guidelines for alzheimer’s disease. Alzheimers Dement 2011;7:280-92.
Reaume AG, Howland DS, Trusko SP, et al. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the swedish familial alzheimer’s disease mutations and a “Humanized” Abeta sequence. J Biol Chem 1996;271:23380-8.
Holmes C, Boche D, Wilkinson D, et al. Long-term effects of abeta42 immunisation in alzheimer’s disease: Follow-up of a randomised, placebo-controlled phase i trial. Lancet 2008;372:216-223.
Nordberg A: Amyloid imaging in early detection of alzheimer’s disease. Neurodegener Dis 2010;7:136-8.
Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer pittsburgh compound-b reflects the amount of amyloid-beta in alzheimer’s disease brain but not in transgenic mouse brain. J Neurosci 2005;25:10598-606.
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in alzheimer’s disease with pittsburgh compound -b. Ann Neurol 2004;55:306-19.
Nakada T, Matsuzawa H, Igarashi H, et al. In vivo visualization of senile-plaque-like pathology in alzheimer’s disease patients by mr microscopy on a 7t system. J Neuroimaging 2008;18:125-9.
Wang Y, Klunk WE, Debnath ML, et al. Development of a pet/spect agent for amyloid imaging in alzheimer’s disease. J Mol Neurosci 2004;24:55-62.
Lockhart A, Lamb JR, Osredkar T, et al. Pib is a nonspecific imaging marker of amyloid-beta (abeta) peptiderelated cerebral amyloidosis. Brain 2007;130:2607-15.
Ng S, Villemagne VL, Berlangieri S, et al. Visual assessment versus quantitative assessment of 11c-pib pet and 18f-fdg pet for detection of alzheimer’s disease. J Nucl Med 2007;48:547-52.
Hintersteiner M, Enz A, Frey P, et al. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol 2005;23:577-83.
Koronyo Y, Salumbides BC, Black KL, et al. Alzheimer’s disease in the retina: imaging retinal aβ plaques for early diagnosis and therapy assessment. Neurodegener Dis 2012;10:285-93.
Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer’s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 2011;54 Suppl 1:S204-17.
Chiu K, Chan TF, Wu A, et al. Neurodegeneration of the retina in mouse models of alzheimer’s disease: What can we learn from the retina? μAge (Dordr)§ 2012;34:633-49.
Dhillon N, Aggarwal BB, Newman RA, et al. Phase ii trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008;14:4491-9.
Alzheimer’s and Dementia. “2015 Alzheimer’s disease facts and figures”. Washington, DC: Alzheimer’s Association Public Policy Office. (Accessed July 20, 2015 at https://www.alz.org/facts/downloads/facts_fi gures_2015.pdf).
Ning A, Cui J, To E, et al. Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci 2008;49:5136-43.
Perez SE, Lumayag S, Kovacs B, et al. Beta-amyloid deposition and functional impairment in the retina of the APP swe/ps1DeltaE9 transgenic mouse model of Alzheimer’s disease. Invest Ophthalmol Vis Sci 2009; 50:793-800.
Liu B, Rasool S, Yang Z, et al. Amyloid-peptide vaccinations reduce beta-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer’s transgenic mice. Am J Pathol 2009;175:2099-110.
Alexandrov PN, Pogue A, Bhattacharjee S, et al. Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer’s disease. Neuroreport 2011;22: 623-7.
Tsai YC, Lu B, Ljubimov AV, et al. Ocular Changes in TgF344-AD Rat Model of Alzheimer’s Disease. Invest Ophthalmol Vis Sci 2014;55:523-34.
Guo L, Salt TE, Luong V, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA 2007; 104:13444-9.
Liu B, Rasool S, Yang Z, et al. Amyloid-peptide vaccinations reduce beta-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer’s transgenic mice. Am J Pathol 2009;175: 2099-110.
